265
Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we
learned? Annu Rev Immunol 19:163–196
Francisci D, Falcinelli E, Baroncelli S, Petito E, Cecchini E, Weimer LE, Floridia M, Gresele P,
Baldelli F (2014) Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a
pilot study of inflammation, endothelial dysfunction, and coagulation markers. Scand J Infect
Dis 46:466–470
Furst R, Zundorf I (2014) Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediat Inflamm
2014:146832
Garcia-Marcos L, Schuster A (2001) Antileukotrienes in asthma: present situation. Expert Opin
Pharmacother 2:441–466
Greene ER, Huang S, Serhan CN, Panigrahy D (2011) Regulation of inflammation in cancer by
eicosanoids. Prostaglandins Other Lipid Mediat 96:27–36
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899
Hampel U, Sesselmann S, Iserovich P, Sel S, Paulsen F, Sack R (2013) Chemokine and cytokine
levels in osteoarthritis and rheumatoid arthritis synovial fluid. J Immunol Methods 396:134–139
Handa P, Kowdley KV (2013) Chemokines: potent mediators of hepatic inflammation and fibrosis
in chronic liver diseases. Ann Hepatol 13:152–154
Harter WG, Albrect H, Brady K, Caprathe B, Dunbar J, Gilmore J, Hays S, Kostlan CR, Lunney
B, Walker N (2004) The design and synthesis of sulfonamides as caspase-1 inhibitors. Bioorg
Med Chem Lett 14:809–812
Haspel RL, Hillmen P (2008) Which patients with paroxysmal nocturnal hemoglobinuria (PNH)
should be treated with eculizumab? ASH evidence-based review 2008. Hematology Am Soc
Hematol Educ Program 2008:35
Hedqvist P, Dahlen SE, Palmertz U (1985) Leukotrienes as mediators of airway anaphylaxis. Adv
Prostaglandin Thromboxane Leukot Res 15:345–348
Holers VM (2016) Targeting mechanisms at sites of complement activation for imaging and therapy. Immunobiology 221(6):726–732
Jablonowski JA, Carruthers NI, Thurmond RL (2004) The histamine H4 receptor and potential
therapeutic uses for H4 ligands. Mini-Rev Med Chem 4:993–1000
Jang MH, Seoh JY, Miyasaka M (2006) Cytokines, chemokines, and their receptors: targets
for immunomodulation. Conference report: international cytokine society conference 2005.
J Leukoc Biol 80:217–219
Kadioglu A, Sheldon P (1996) Adhesion of rheumatoid lymphocytes to mucosal endothelium: the
gut revisited. Br J Rheumatol 35:218–225
Keating GM (2013) Eculizumab: a review of its use in atypical haemolytic uraemic syndrome.
Drugs 73:2053–2066
Kemp JP (2003) Recent advances in the management of asthma using leukotriene modifiers. Am
J Respir Med 2:139–156
Khanapure SP, Garvey DS, Janero DR, Letts LG (2007) Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem 7:311–340
Kirschfink M (2001) Targeting complement in therapy. Immunol Rev 180:177–189
Kiss R, Keseru GM (2012) Histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opin Ther Pat 22:205–221
Kiss R, Keseru GM (2014) Novel histamine H4 receptor ligands and their potential therapeutic
applications: an update. Expert Opin Ther Pat 24:1185–1197
Krystal AD, Richelson E, Roth T (2013) Review of the histamine system and the clinical effects of
H1 antagonists: basis for a new model for understanding the effects of insomnia medications.
Sleep Med Rev 17:263–272
Lam BK, Lee CY, Wong PY (1988) Phospholipase A2 (PLA2) releases lipoxins and leukotrienes
from endogenous sources. Ann N Y Acad Sci 524:27–34
10 Anti-inflammatory Molecules: Immune System Mediators
Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we
learned? Annu Rev Immunol 19:163–196
Francisci D, Falcinelli E, Baroncelli S, Petito E, Cecchini E, Weimer LE, Floridia M, Gresele P,
Baldelli F (2014) Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a
pilot study of inflammation, endothelial dysfunction, and coagulation markers. Scand J Infect
Dis 46:466–470
Furst R, Zundorf I (2014) Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediat Inflamm
2014:146832
Garcia-Marcos L, Schuster A (2001) Antileukotrienes in asthma: present situation. Expert Opin
Pharmacother 2:441–466
Greene ER, Huang S, Serhan CN, Panigrahy D (2011) Regulation of inflammation in cancer by
eicosanoids. Prostaglandins Other Lipid Mediat 96:27–36
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899
Hampel U, Sesselmann S, Iserovich P, Sel S, Paulsen F, Sack R (2013) Chemokine and cytokine
levels in osteoarthritis and rheumatoid arthritis synovial fluid. J Immunol Methods 396:134–139
Handa P, Kowdley KV (2013) Chemokines: potent mediators of hepatic inflammation and fibrosis
in chronic liver diseases. Ann Hepatol 13:152–154
Harter WG, Albrect H, Brady K, Caprathe B, Dunbar J, Gilmore J, Hays S, Kostlan CR, Lunney
B, Walker N (2004) The design and synthesis of sulfonamides as caspase-1 inhibitors. Bioorg
Med Chem Lett 14:809–812
Haspel RL, Hillmen P (2008) Which patients with paroxysmal nocturnal hemoglobinuria (PNH)
should be treated with eculizumab? ASH evidence-based review 2008. Hematology Am Soc
Hematol Educ Program 2008:35
Hedqvist P, Dahlen SE, Palmertz U (1985) Leukotrienes as mediators of airway anaphylaxis. Adv
Prostaglandin Thromboxane Leukot Res 15:345–348
Holers VM (2016) Targeting mechanisms at sites of complement activation for imaging and therapy. Immunobiology 221(6):726–732
Jablonowski JA, Carruthers NI, Thurmond RL (2004) The histamine H4 receptor and potential
therapeutic uses for H4 ligands. Mini-Rev Med Chem 4:993–1000
Jang MH, Seoh JY, Miyasaka M (2006) Cytokines, chemokines, and their receptors: targets
for immunomodulation. Conference report: international cytokine society conference 2005.
J Leukoc Biol 80:217–219
Kadioglu A, Sheldon P (1996) Adhesion of rheumatoid lymphocytes to mucosal endothelium: the
gut revisited. Br J Rheumatol 35:218–225
Keating GM (2013) Eculizumab: a review of its use in atypical haemolytic uraemic syndrome.
Drugs 73:2053–2066
Kemp JP (2003) Recent advances in the management of asthma using leukotriene modifiers. Am
J Respir Med 2:139–156
Khanapure SP, Garvey DS, Janero DR, Letts LG (2007) Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem 7:311–340
Kirschfink M (2001) Targeting complement in therapy. Immunol Rev 180:177–189
Kiss R, Keseru GM (2012) Histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opin Ther Pat 22:205–221
Kiss R, Keseru GM (2014) Novel histamine H4 receptor ligands and their potential therapeutic
applications: an update. Expert Opin Ther Pat 24:1185–1197
Krystal AD, Richelson E, Roth T (2013) Review of the histamine system and the clinical effects of
H1 antagonists: basis for a new model for understanding the effects of insomnia medications.
Sleep Med Rev 17:263–272
Lam BK, Lee CY, Wong PY (1988) Phospholipase A2 (PLA2) releases lipoxins and leukotrienes
from endogenous sources. Ann N Y Acad Sci 524:27–34
10 Anti-inflammatory Molecules: Immune System Mediators